Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 15 · below the Ichimoku cloud · RSI 42 · MACD below its signal · at its 52-week low
| 0.001000 | 52-week high | +900.00% |
| 0.000400 | Previous month high | +300.00% |
| 0.000300 | Previous week high | +200.00% |
| 0.000100 | Price now | |
| 0.000100 | R3 (classic) | −0.00% |
| 0.000100 | R2 (classic) | −0.00% |
| 0.000100 | R1 (classic) | −0.00% |
| 0.000100 | Pivot | −0.00% |
| 0.000100 | S1 (classic) | −0.00% |
| 0.000100 | S2 (classic) | −0.00% |
| 0.000100 | S3 (classic) | −0.00% |
| 0.000100 | Previous day high | −0.00% |
| 0.000100 | Previous day low | −0.00% |
| 0.000100 | Previous week low | −0.00% |
| 0.000100 | Previous month low | −0.00% |
| 0.000100 | 52-week low | −0.00% |
None of the 29 investors followed here reported a position in CALA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CALA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for CALA.
TimeframesDown on the hourly, daily and weekly, mixed on the monthly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 100.0 | -50.0 | 200.0 | -33.3 | 100.0 | -25.0 | 0.0 | 0.0 | -66.7 | 0.0% | ||
| 2025 | 500.0 | 0.0 | 0.0 | 733.3 | -45.0 | -63.6 | -90.0 | 100.0 | -50.0 | 100.0 | 0.0 | -50.0 | −0.0% |
| 2024 | 0.0 | -33.3 | 22.8 | -18.5 | -50.0 | 0.0 | 25.0 | -20.0 | -90.0 | 600.0 | 10.0 | -98.7 | −99.7% |
| 2023 | -87.4 | -85.4 | -8.3 | -63.6 | 1700.0 | -83.3 | -16.7 | 0.0 | 0.0 | -35.0 | -3.8 | -4.0 | −99.1% |
| 2022 | -2.3 | -25.4 | -16.7 | -39.2 | -16.4 | -40.1 | 29.3 | 22.3 | -24.4 | -14.6 | -22.3 | 67.2 | −75.5% |
| 2021 | -41.5 | 1.7 | -17.1 | -10.3 | 5.1 | -8.3 | -6.7 | 25.6 | -11.0 | -11.5 | -57.1 | -19.6 | −86.5% |
| 2020 | 5.1 | 8.0 | -31.5 | 38.1 | -5.1 | -9.3 | -11.0 | -14.3 | -14.4 | 2.6 | 38.7 | 0.0 | −14.0% |
| 2019 | 11.2 | 24.4 | 21.4 | -8.6 | -14.6 | -25.9 | 8.7 | -6.4 | -22.2 | -6.8 | 70.8 | 16.1 | +42.4% |
| 2018 | -4.2 | -3.8 | -18.2 | -2.4 | -16.3 | -2.9 | -11.0 | 22.5 | -3.7 | -10.1 | 4.4 | -18.7 | −52.0% |
| 2017 | 115.4 | 28.6 | 28.3 | -6.1 | 43.3 | -4.5 | 3.0 | 7.2 | -4.0 | 2.2 | -34.8 | -20.5 | +156.9% |
| 2016 | -34.7 | 18.8 | -4.4 | -6.2 | -1.7 | -29.2 | -14.6 | -2.2 | 4.8 | -15.4 | 27.3 | -7.1 | −57.6% |
| 2015 | -1.5 | -23.5 | 7.9 | -39.0 | 4.6 | -31.8 | 3.6 | -21.2 | -6.9 | 57.3 | -7.0 | -3.5 | −62.1% |
| 2014 | 13.3 | 89.3 | +114.4% |
No analyst coverage for this instrument.
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.